Drugs / AlloNK1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07247201 | Apr 2026 overdue | nasopharyngeal carcinoma | Singapore General Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AlloNK1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07247201 ↗ |
| Known as | Allogenic expanded Natural Killer Cells | “Allogenic expanded Natural Killer Cells (AlloNK1)” NCT07247201 ↗ |
| Modality | Cell therapy | “NK cell therapy” NCT07247201 ↗ |
| Route | Intravenous | “six intravenous NK cell infusions” NCT07247201 ↗ |